Compare CSPI & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | CGTX |
|---|---|---|
| Founded | 1968 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.1M | 94.5M |
| IPO Year | 1994 | 2021 |
| Metric | CSPI | CGTX |
|---|---|---|
| Price | $7.94 | $1.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 17.4K | ★ 605.9K |
| Earning Date | 05-13-2026 | 03-26-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | ★ 75.00 | 62.79 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $58,730,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $817.00 | ★ N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $7.98 | $0.22 |
| 52 Week High | $17.76 | $3.83 |
| Indicator | CSPI | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.86 | 46.31 |
| Support Level | N/A | $1.01 |
| Resistance Level | $9.08 | $1.19 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 7.81 | 35.00 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.